| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/20/2003 | WO2003013537A2 Irinotecan for treatment of cancer |
| 02/20/2003 | WO2003013536A2 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 02/20/2003 | WO2003013535A2 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 02/20/2003 | WO2003013534A2 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 02/20/2003 | WO2003013533A2 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 02/20/2003 | WO2003013532A1 Chiral dinapsoline |
| 02/20/2003 | WO2003013531A1 Phenyl derivatives as factor xa inhibitors |
| 02/20/2003 | WO2003013530A2 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists |
| 02/20/2003 | WO2003013529A1 Paroxetine glycyrrhizinate |
| 02/20/2003 | WO2003013528A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists. |
| 02/20/2003 | WO2003013527A1 Sulfonamide derivatives as gamma secretase inhibitors |
| 02/20/2003 | WO2003013526A1 Anticoagulant compounds |
| 02/20/2003 | WO2003013525A1 Opioid agonist formulations with releasable and sequestered antagonist |
| 02/20/2003 | WO2003013524A1 Treatment of refractory depression with an opiate antagonist and an antidepressant |
| 02/20/2003 | WO2003013523A1 Sh3 protein domains and their ligands |
| 02/20/2003 | WO2003013522A1 Preventives/remedies for cholinergic neuropathy |
| 02/20/2003 | WO2003013521A1 Compounds for eliminating and/or relieving anhedonia |
| 02/20/2003 | WO2003013520A1 Pramipexole for the treatment of adhd |
| 02/20/2003 | WO2003013519A1 Pramipexol as an anticonvulsive agent |
| 02/20/2003 | WO2003013518A1 Alpha-ketoamide derivatives as cathepsin k inhibitors |
| 02/20/2003 | WO2003013517A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 02/20/2003 | WO2003013516A1 Fat accumulation-modulating compounds |
| 02/20/2003 | WO2003013515A1 Novel alpha adrenergic agents |
| 02/20/2003 | WO2003013514A1 Improving neurological functions |
| 02/20/2003 | WO2003013513A1 Stable emulsion composition |
| 02/20/2003 | WO2003013512A2 Crystalline forms of fluvastatin sodium |
| 02/20/2003 | WO2003013511A1 Integrin inhibitors for the treatment of eye diseases |
| 02/20/2003 | WO2003013510A1 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
| 02/20/2003 | WO2003013509A1 N-phenylpyrrole guanidine derivatives as melanocortin reception ligands |
| 02/20/2003 | WO2003013508A1 Therapeutic agent for depletion of an unwanted protein population from plasma |
| 02/20/2003 | WO2003013507A1 Method of preventing or reducing the occurrence of symptoms of psychosis |
| 02/20/2003 | WO2003013505A1 Drugs for treatment of cerebral injury and methods of use thereof |
| 02/20/2003 | WO2003013504A1 Diacyglycerol mimetics and methods of using the same as protein kinase c alpha activators and apoptosis inducers |
| 02/20/2003 | WO2003013503A1 C-2' methylated derivatives of paclitaxel for use as antitumour agents |
| 02/20/2003 | WO2003013502A1 Compounds which mimic the chemical and biological properties of discodermolide |
| 02/20/2003 | WO2003013501A1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
| 02/20/2003 | WO2003013500A1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
| 02/20/2003 | WO2003013499A2 Drugs for vasculopaties |
| 02/20/2003 | WO2003013498A2 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases |
| 02/20/2003 | WO2003013497A1 Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction |
| 02/20/2003 | WO2003013496A1 Reduction of hair growth |
| 02/20/2003 | WO2003013494A1 Remedial agent for arthrosis deformans |
| 02/20/2003 | WO2003013493A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs |
| 02/20/2003 | WO2003013492A1 Combination therapy for the treatment of neurological disorders |
| 02/20/2003 | WO2003013491A1 Synergistic microbicidal compositions |
| 02/20/2003 | WO2003013490A1 Nutricional and therapeutical preparations having antioxidant activity |
| 02/20/2003 | WO2003013489A1 Treatment of nail infections with no |
| 02/20/2003 | WO2003013488A2 Methods and compositions for inhibiting rad51 |
| 02/20/2003 | WO2003013487A2 Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field |
| 02/20/2003 | WO2003013486A1 The treatment of lipodystrophy |
| 02/20/2003 | WO2003013485A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma |
| 02/20/2003 | WO2003013484A2 N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents |
| 02/20/2003 | WO2003013483A1 Coated filter bag material for oral administration of medicament in liquid and methods of making same |
| 02/20/2003 | WO2003013481A1 The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients |
| 02/20/2003 | WO2003013479A1 Compositions and methods to prevent abuse of opioids |
| 02/20/2003 | WO2003013478A2 Method of encapsulating an active substance |
| 02/20/2003 | WO2003013477A1 Drug release system for controlled therapy |
| 02/20/2003 | WO2003013476A1 Compositions and methods to prevent abuse of opioids |
| 02/20/2003 | WO2003013475A1 Injectable foam and novel pharmaceutical applications thereof |
| 02/20/2003 | WO2003013474A1 Nanoparticulate formulations of fenofibrate |
| 02/20/2003 | WO2003013473A1 Stabilized oral suspension formulation |
| 02/20/2003 | WO2003013470A1 Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt |
| 02/20/2003 | WO2003013449A2 Method of reducing hair growth by applying alpha-difluoromethylornithine |
| 02/20/2003 | WO2003013445A1 Nanocapsules containing a steroid for cosmetic compositions |
| 02/20/2003 | WO2003013442A2 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
| 02/20/2003 | WO2003013441A2 Levothyroxine compositions and methods |
| 02/20/2003 | WO2003013440A2 Treatment and prevention of heat shock protein-associated diseases and conditions |
| 02/20/2003 | WO2003013438A2 Nutrient therapy for immuno-compromised patients |
| 02/20/2003 | WO2003013436A2 Kavalactone compositions and methods of use |
| 02/20/2003 | WO2003013434A2 Methods and compositions for treating diseases associated with excesses in ace |
| 02/20/2003 | WO2003013433A2 Sequestered antagonist formulations |
| 02/20/2003 | WO2003013432A2 Methods of use for novel sulfur containing organic nitrate compounds |
| 02/20/2003 | WO2003013424A2 Use of r-nsaid compounds for anti-hiv treatment |
| 02/20/2003 | WO2003013283A1 Stable and bioavailable iron fortified beverages |
| 02/20/2003 | WO2003013277A1 Chitosan-containing powder |
| 02/20/2003 | WO2003013276A1 Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level |
| 02/20/2003 | WO2003013275A1 Composition for lowering blood cholesterol |
| 02/20/2003 | WO2003013270A2 Calcium dietary supplement |
| 02/20/2003 | WO2003013245A1 Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
| 02/20/2003 | WO2003006001A8 ss-ADRENERGIC BLOCKADE REVERSAL OF CATABOLISM AFTER SEVERE BURN |
| 02/20/2003 | WO2002102794A3 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 02/20/2003 | WO2002100858A3 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors |
| 02/20/2003 | WO2002099138A3 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2002098427A3 Sustained-release analgesic compounds |
| 02/20/2003 | WO2002098390A3 Delivery of aerosols containing small particles through an inhalation route |
| 02/20/2003 | WO2002096945A3 Macrophage receptor agonist or antagonist |
| 02/20/2003 | WO2002096927A3 Ribozyme based treatment of female reproductive diseases |
| 02/20/2003 | WO2002096516A8 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 02/20/2003 | WO2002096422A3 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
| 02/20/2003 | WO2002089815A3 Disinfecting and solubilizing steroid compositions |
| 02/20/2003 | WO2002088323A3 Gene delivery compounds |
| 02/20/2003 | WO2002088069A3 Compounds useful as intermediates for 4-aminoquinoline derivatives |
| 02/20/2003 | WO2002085789A3 Magnesium di-pot assium edta complex and method of administration |
| 02/20/2003 | WO2002085375A8 Novel hormone composition |
| 02/20/2003 | WO2002085368A3 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/20/2003 | WO2002085291A3 Nociceptin analogs |
| 02/20/2003 | WO2002080889A3 A combination dosage of a cyclooxygenase (cox) inhibitor, a vitamin d3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer |
| 02/20/2003 | WO2002080668A3 Antimicrobial formulations |
| 02/20/2003 | WO2002079183A8 Halogenated rhodamine derivatives and applications thereof |
| 02/20/2003 | WO2002078602A3 Transdermal delivery of pergolide |